AR129270A1 - Profármacos y usos de los mismos - Google Patents
Profármacos y usos de los mismosInfo
- Publication number
- AR129270A1 AR129270A1 ARP230101137A ARP230101137A AR129270A1 AR 129270 A1 AR129270 A1 AR 129270A1 AR P230101137 A ARP230101137 A AR P230101137A AR P230101137 A ARP230101137 A AR P230101137A AR 129270 A1 AR129270 A1 AR 129270A1
- Authority
- AR
- Argentina
- Prior art keywords
- dkp
- thz
- formula
- relates
- prodrugs
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22172545 | 2022-05-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR129270A1 true AR129270A1 (es) | 2024-08-07 |
Family
ID=81940650
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP230101137A AR129270A1 (es) | 2022-05-10 | 2023-05-09 | Profármacos y usos de los mismos |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20250304645A1 (enExample) |
| EP (1) | EP4522220A1 (enExample) |
| JP (1) | JP2025517672A (enExample) |
| CN (1) | CN119173275A (enExample) |
| AR (1) | AR129270A1 (enExample) |
| TW (1) | TW202346324A (enExample) |
| WO (1) | WO2023217744A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025092778A1 (zh) * | 2023-10-31 | 2025-05-08 | 深圳信立泰药业股份有限公司 | Glp-1化合物及其制备方法与应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7238671B2 (en) * | 2001-10-18 | 2007-07-03 | Bristol-Myers Squibb Company | Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions |
| TWI362392B (en) | 2005-03-18 | 2012-04-21 | Novo Nordisk As | Acylated glp-1 compounds |
| PE20120332A1 (es) | 2008-12-19 | 2012-04-14 | Univ Indiana Res & Tech Corp | Profarmacos de peptido de la superfamilia de glucagon basado en amida |
| WO2010080605A1 (en) | 2008-12-19 | 2010-07-15 | Indiana University Research And Technology Corporation | Dipeptide linked medicinal agents |
| ES2401965T3 (es) | 2009-02-19 | 2013-04-25 | Novo Nordisk A/S | Modificación de Factor VIII |
| JP6006118B2 (ja) | 2009-12-16 | 2016-10-12 | ノヴォ ノルディスク アー／エス | Ｇｌｐ−１アナログ及び誘導体 |
| US9062094B2 (en) | 2010-01-22 | 2015-06-23 | Ascendis Pharma As | Dipeptide-based prodrug linkers for aliphatic amine-containing drugs |
| EP2588126A4 (en) | 2010-06-24 | 2015-07-08 | Univ Indiana Res & Tech Corp | AMID-BASED GLUCAGON SUPERFAMILY PEPTIDE PRODRUGS |
| JP6039569B2 (ja) | 2010-11-09 | 2016-12-07 | ノヴォ ノルディスク アー／エス | 二重アシル化されたｇｌｐ−１誘導体 |
| US9452225B2 (en) | 2012-03-01 | 2016-09-27 | Novo Nordisk A/S | GLP-1 prodrugs |
| JP2016521253A (ja) | 2013-03-15 | 2016-07-21 | インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション | 持続性作用を有するプロドラッグ |
| JP6701208B2 (ja) | 2014-09-24 | 2020-05-27 | インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション | 脂質化アミド系インスリンプロドラッグ |
| JP6898518B2 (ja) | 2018-02-02 | 2021-07-07 | ノヴォ ノルディスク アー／エス | Ｇｌｐ−１アゴニスト、ｎ−（８−（２−ヒドロキシベンゾイル）アミノ）カプリル酸の塩及び滑沢剤を含む固形組成物 |
| TWI829687B (zh) | 2018-05-07 | 2024-01-21 | 丹麥商諾佛 儂迪克股份有限公司 | 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物 |
-
2023
- 2023-05-09 AR ARP230101137A patent/AR129270A1/es unknown
- 2023-05-09 US US18/864,190 patent/US20250304645A1/en active Pending
- 2023-05-09 JP JP2024566410A patent/JP2025517672A/ja active Pending
- 2023-05-09 CN CN202380039160.4A patent/CN119173275A/zh active Pending
- 2023-05-09 TW TW112117140A patent/TW202346324A/zh unknown
- 2023-05-09 EP EP23726891.7A patent/EP4522220A1/en active Pending
- 2023-05-09 WO PCT/EP2023/062208 patent/WO2023217744A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| CN119173275A (zh) | 2024-12-20 |
| WO2023217744A1 (en) | 2023-11-16 |
| US20250304645A1 (en) | 2025-10-02 |
| TW202346324A (zh) | 2023-12-01 |
| JP2025517672A (ja) | 2025-06-10 |
| EP4522220A1 (en) | 2025-03-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2561108T3 (es) | Composiciones inyectables para la liberación controlada de compuesto farmacológicamente activo | |
| AR072610A1 (es) | Composiciones para el tratamiento del dolor y/o la inflamacion | |
| AR126076A1 (es) | Compuestos de benzotia(di)azepina y su uso como moduladores del ácido biliar | |
| ES2683860T3 (es) | Compuestos de succinato con permeabilidad celular novedosos | |
| AR035365A1 (es) | Compuesto peptidico que comprende un centro inhibidor de la metionina aminopeptidasa 2 (metap-2) y su uso para preparar un medicamento | |
| AR033356A1 (es) | Compuesto que contiene una cadena lateral heterociclica, composicion farmaceutica que lo comprende y uso de dicho compuesto para la fabricacion de un medicamento | |
| DE69832982T2 (de) | Dolastatin 15 derivate | |
| CO2023005973A2 (es) | Profármacos de glp-1 y usos de los mismos | |
| AR033678A1 (es) | Derivados de quinolina, procedimiento para prepararlos, uso de los mismos para la preparacion de medicamentos y los medicamentos que contienen dichos derivados | |
| AR033383A1 (es) | Derivados de acridina, procedimiento para prepararlos, el uso de los mismos para la preparacion de medicamentos y los medicamentos que contienen dichos derivados | |
| AR032467A1 (es) | Derivados de piridina, procedimiento para prepararlos, el uso de dichos derivados para la preparacion de medicamentos y los medicamentos que contienen dichos derivados | |
| FR2985258A1 (fr) | Composes dimeres agonistes des recepteurs des fgfs (fgfrs), leur procede de preparation et leur application en therapeutique | |
| ES2670394T3 (es) | Inhibidores de ciclofilinas para utilizar en la prevención y/o el tratamiento de patologías virales o infecciones | |
| JPWO2003070754A1 (ja) | ヒストン脱アセチル化酵素阻害剤およびその製造方法 | |
| AR129270A1 (es) | Profármacos y usos de los mismos | |
| AR005827A1 (es) | Compuesto derivado de nucleosidos aciclicos, composicion farmaceutica que lo comprende, uso del mismo en la preparacion de un medicamento y su metodo de preparacion | |
| AR048973A1 (es) | (4-metoxi-7-morfolin-4-il-benzotiazol-2-il)amida del acido 4-hidroxi-4-metil-piperidin-1-carboxilico. proceso de preparacion y composiciones farmaceuticas | |
| AU2005265164A2 (en) | Non-natural amino acids | |
| WO2023059792A1 (en) | Coronavirus non-structural protein 3 degrading compounds | |
| CA2064592A1 (fr) | Derives d'amino-acides, leur procede de preparation et leur application therapeutique | |
| WO2019110837A1 (fr) | Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacide | |
| AR012436A1 (es) | Compuestos de 4-aminopirido[2,3-d]pirimidina 5,7-disustituidos, composicion farmaceutica que los comprende, el uso de los mismos para lamanufactura de medicamentos, un procedimiento para su preparacion. | |
| AR030197A1 (es) | Compuesto n-sustituido que contiene una cadena lateral heterociclica, composicion farmaceutica que lo comprende y uso de dicho compuesto para la fabricacion de un medicamento | |
| ES2641992T3 (es) | Compuestos de pirimidina bicíclicos sustituidos | |
| AR004264A1 (es) | Compuesto beta-amino ester de alcoholes perfumados para su uso en composiciones para lavado de ropa y limpieza de superficies duras, proceso depreparacion, metodo de uso. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |